RT Journal Article
SR Electronic
T1 Hospital admissions for acute respiratory tract infections among infants from Nunavut and the burden of respiratory syncytial virus: a 10-year review in regional and tertiary hospitals
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.02.21.24303174
DO 10.1101/2024.02.21.24303174
A1 Kinshella, Mai-Lei Woo
A1 Allen, Jean
A1 Pawa, Jasmine
A1 Papenburg, Jesse
A1 Jetty, Radha
A1 Dwilow, Rachel
A1 Embree, Joanne
A1 Robinson, Joan
A1 Arbour, Laura
A1 Sadarangani, Manish
A1 Shen, Ye
A1 Bone, Jeffrey N.
A1 Walker, Celia
A1 Kayda, Iryna
A1 Sheffield, Holden
A1 Scott, Darcy
A1 Miners, Amber
A1 Goldfarb, David M.
YR 2024
UL http://medrxiv.org/content/early/2024/03/06/2024.02.21.24303174.abstract
AB Background Nunavut is a northern Canadian territory in Inuit Nunangat (Inuit homeland in Canada). Approximately 85% of the population identifies as Inuit. A high proportion of infants in Nunavut are admitted to hospital with acute respiratory tract infection (ARI) but previous studies have been limited in regional and/or short duration of coverage. This study aimed to estimate the incidence rate, microbiology and outcomes of ARI hospitalizations in Nunavut infants.Methods We conducted chart reviews with a retrospective cohort of infants aged <1 year from Nunavut at six Canadian hospitals, including two regional and four tertiary pediatric hospitals January 1, 2010, to June 30, 2020. Descriptive statistics and multivariable logistic regression were performed.Results We identified 1189 ARI admissions of infants during the study period, with an incidence rate of 133.9 per 1000 infants per year (95% confidence interval (CI): 126.8, 141.3). Of these admissions, 56.0% (n=666) were to regional hospitals alone, 72.3% (n=860) involved hospitalization outside of Nunavut, 15.6% (n=185) were admitted into intensive care, and 9.2% (n=109) underwent mechanical ventilation. Of the 730 admissions with a pathogen identified, 45.8% had respiratory syncytial virus (RSV; n=334), for a yearly incidence rate of 37.8 hospitalizations per 1000 infants (95% CI: 33.9, 42.1). Among RSV hospitalizations, 41.1% (n=138) were infants 0-2 months of age and 32.1% (n=108) were > 6months.Interpretation Understanding the high burden of ARI among Nunavut infants can inform health policy and serve as a baseline for assessing the impact of any new interventions targeting infant ARIs.Competing Interest StatementDr Papenburg reported grants and personal fees from Merck, personal fees from AstraZeneca, and grants from MedImmune outside the submitted work. Dr Robinson received an Honoria from the Alberta Pharmacists' Association (RxA) for a talk on RSV September 2023 and has received consulting fees from Elsevier for peer review of FUO section of Clinical Overviews in 2023, both outside the submitted work. Dr Sadarangani has been an investigator on projects funded by GlaxoSmithKline, Merck, Moderna, Pfizer and Sanofi-Pasteur. All funds have been paid to his institute, and he has not received any personal payments. The remaining authors declare no conflicts of interest.Funding StatementThis work was supported by the Canadian Immunization Research Network (CIRN) through a grant from the Public Health Agency of Canada and the Canadian Institutes of Health Research (CNF 151944). The funders had no role in the study design, analysis, interpretation of the results, or decision to publish.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Children and Women Research Ethics Board of the University of British Columbia gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors